The Autistic Spectrum Disorders

Clinical Child Psychiatry: Second Edition

Volumn , Issue , 2006, Pages 371-389

  Owley, Tom ^a   Leventhal, Bennett L ^a   Cook, Edwin H ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Asperger disorder and autistic disorder; Autism Diagnostic Interview Revised (ADI R); Autism spectrum disorders (ASDs); Autistic spectrum disorders; Glutamatergic antagonists; Hyperserotonemia; Pervasive developmental disorder not otherwise specified (PDD NOS); Psychological testing; Rett disorder in female child

Indexed keywords

EID: 77549088571     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/0470022116.ch21     Document Type: Chapter

References (153)

1. Chakrabarti S, Fombonne E: Pervasive developmental disorders in preschool children. JAMA 2001; 285:3093-3099.
2. Fombonne E: The epidemiology of autism: A review. Psychol Med 1999; 29:769-786.
3. Zahner G, Pauls D: Epidemiological surveys of infantile autism. In: Cohen D, Donnellan A, eds. Handbook of Autism and Pervasive Developmental Disorders. New York: John Wiley and Sons, 1987:199-210.
4. Ritvo ER, Jorde LB, Mason-Brothers A, Freeman BJ, Pingree C, Jones MB, McMahon WM, Peterson PB, Jenson WR, Mo A: The UCLA-University of Utah epidemiologic survey of autism: Recurrent risk estimates and genetic counseling. Am J Psych 1989; 146: 1032-1036.
5. Volkmar F, Klin A, Siegel B, Szatmari P, Lord C, Campbell M, Freeman B, Cicchetti D, Rutter M, Kline W, Buitelaar J, Hattab Y, Fombonne E, Fuentes J, Werry J, Stone W, Kerbeshian J, Hoshino Y, Bregman J, Loveland K, et al.: Field trial for autistic disorder in DSM-IV. Am J Psychiatry 1994; 151:1361-1367.
6. Kurita H, Kita M, Miyake Y: A comparative study of development and symptoms among disintegrative psychosis and infantile autism with and without speech loss. J Autism Dev Disord 1992; 22:175-188.
7. Freeman BJ, Ritvo ER, Needleman R, Yokota A: The stability of cognitive and linguistic parameters in autism: A five-year prospective study. J Am Acad Child Psychiatry 1985; 24:459-464.
8. Venter A, Lord C, Schopler E: A follow-up study of high-functioning autistic children. J Child Psychol Psychiat 1992; 33:489-507.
9. Rutter M: Cognitive deficits in the pathogenesis of autism. J Child Psychol Psychiat 1993; 24:513-532.
10. Frith U: Autism: Explaining the Enigma. New York: Blackwell, 1989.
11. Schain RJ, Freedman DX: Studies on 5-hydroxyindole metabolism in autistic and other mentally retarded children. J Pediatrics 1961; 58:315-320.
12. Anderson GM, Freedman DX, Cohen DJ, Volkmar FR, Hoder EL, McPhedran P, Minderaa RB, Hansen CR, Young JG: Whole blood serotonin in autistic and normal subjects. J Child Psychol Psychiatry 1987; 28: 885-900.
13. Cook E, Arora R, Anderson G, Berry-Kravis E, Yan SY, Yeoh H, Sklena P, Charak D, Leventhal B: Platelet serotonin studies in hyperserotonemic relatives of children with autistic disorder. Life Sci 1993; 52:2005-2015.
14. 2A receptor. J Neurochem 1994; 63:465-469.
15. Bailey A, Bolton P, Butler L, Le Couteur A, Murphy M, Scott S, Webb T, Rutter M: Prevalence of the fragile X anomaly amongst autistic twins and singletons. J Child Psychol Psychiatry 1993; 34(5):673-688.
16. Reiss AL, Freund L: Fragile X syndrome, DSM-III-R, and autism. J Am Acad Child Adolesc Psychiatry 1990; 29:885-891.
17. Gillberg C, Steffenburg S, Wahlström J, Gillberg I, Sjöstedt A, Martinsson T, Liedgren S, Eeg-Olofsson O: Autism associated with marker chromosome. J Am Acad Child Adolesc Psychiatry 1991; 30:489-494.
18. Cook E, Lindgren V, Leventhal B, Courchesne R, Lincoln A, Shulman C, Lord C, Courchesne E: Autism or atypical autism in maternally but not paternally derived proximal 15q duplication. Am J Hum Genet 1997; 60:928-934.
19. Knoblock H, Pasamanick B: Some etiologic and prognostic factors in early infantile autism and psychosis. Pediatrics 1975; 55:182-191.
20. Smalley SL, Tanguay PE, Smith M, Gutierrez G: Autism and tuberous sclerosis. J Autism Dev Disord 1992; 22:339-355.
21. Buyse IM, Fang P, Hoon KT, Amir RE, Zoghbi HY, Roa BB: Diagnostic testing for Rett syndrome by DHPLC and direct sequencing analysis of the MECP2 gene: Identification of several novel mutations and polymorphisms. Am J Hum Genet 2000; 67: 1428-1436.
22. Bailey A, Le Couteur A, Gottesman I, Bolton P, Simonoff E, Yuzda E, Rutter M: Autism as a strong genetic disorder: Evidence from a British twin study. Psychol Med 1995; 25:63-77.
23. Steffenburg S, Gillberg C, Hellgren L, Andersson L, Gillberg IC, Jakobsson G, Bohman M: A twin study of autism in Denmark, Finland, Iceland, Norway and Sweden. J Child Psychol Psychiat 1989; 30: 405-416.
24. Bailey A, Le Couteur A, Gottesman I, Bolton P, Simonoff E, Yuzda E, Rutter M: Autism as a strongly genetic disorder: Evidence from a British twin study. Psychol Med 1995; 25(1):63-77.
25. Damasio AR, Maurer RG: A neurological model of childhood autism. Arch Neurol 1978; 35:777-786.
26. Volkmar FR, Nelson DS: Seizure disorders in autism. J Am Acad Child Adolesc Psychiatry 1990; 29:127-129.
27. Deykin EY, Macmahon B: The incidence of seizures among children with autistic symptoms. Am J Psychiatry 1979; 136:1310-1312.
28. Rutter M, Greenfield D, Lockyer L: A five to fifteen year follow-up study of infantile psychosis. II. Social and behavioural outcome. Br J Psychiatry 1967; 113: 1183-1199.
29. Ritvo ER, Freeman BJ, Scheibel AB, Duong T, Robinson H, Guthrie D, Ritvo A: Lower Purkinje cell counts in the cerebella of four autistic subjects: Initial findings of the UCLA-NSAC autopsy research report. Am J Psychiatry 1986; 143:862-866.
30. Bauman M, Kemper T: Neuroanatomic observations of the brain in autism. In: Bauman M, Kemper T, eds. The Neurobiology of Autism. Baltimore: Johns Hopkins University Press, 1994:119-145.
31. Casanova MF, Buxhoeveden DP, Switala AE, Roy E: Neuronal density and architecture (Grey Level Index) in the brains of autistic patients. J Child Neurol 2002; 17:515-521.
32. Casanova MF, Buxhoeveden DP, Switala AE, Roy E: Asperger's syndrome and cortical neuropathology. J Child Neurol 2002; 17:142-145.
33. Sparks BF, Friedman SD, Shaw DW, Aylward EH, Echelard D, Artru AA, Maravilla B, Giedd JN, Munson J, Dawson G, Dager SR: Brain structural abnormalities in young children with autism spectrum disorder. Neurology 2002; 59:184-192.
34. Courchesne E, Yeung CR, Press GA, Hesselink JR, Jernigan TL: Hypoplasia of cerebellar vermal lobules VI and VII in autism. N Engl J Med 1988; 318: 1349-1354.
35. Holttum J, Minshew N, Sanders R, Philips N: Magnetic resonance imaging of the posterior fossa in autism. Biol Psychiatry 1992; 32:1091-1101.
36. Saitoh O, Karns CM, Courchesne E: Development of the hippocampal formation from 2 to 42 years: MRI evidence of smaller area dentata in autism. Brain 2001; 124:1317-1324.
37. Herbert MR, Harris GJ, Adrien KT, Ziegler DA, Makris N, Kennedy DN, Lange NT, Chabris CF, Bakardjiev A, Hodgson J, Takeoka M, Tager-Flusberg H, Caviness VS Jr.: Abnormal asymmetry in language association cortex in autism. Ann Neurol 2002; 52: 588-596.
38. Piven J, Arndt S, Bailey J, Havercamp S, Andreasen NC, Palmer P: An MRI study of brain size in autism. Am J Psychiatry 1995; 152:1145-1149.
39. Rumsey JM, Duara R, Grady C, Rapoport JL, Margolin RA, Rapoport SI, Cutler NR: Brain metabolism in autism: Resting cerebral glucose utilization rates as measured with positron emission tomography. Arch Gen Psychiatry 1985; 42:448-455.
40. Herold S, Frackowiak RSJ, Le Couteur A, Rutter M, Howlin P: Cerebral blood flow and metabolism of oxygen and glucose in young autistic adults. Psychol Med 1988; 18:823-831.
41. Chugani HT, Da Silva E, Chugani DC: Infantile spasms: III. Prognostic implications of bitemporal hypometabolism on positron emission tomography. Ann Neurol 1996; 39:943-649.
42. Chugani DC, Muzik O, Rothermel R, Behen M, Chakraborty P, Mangner T, Da Silva E, Chugani HT: Altered serotonin synthesis in the dentatothalamocortical pathway in autism boys. Ann Neuro 1997; 42:666-669.
43. Chugani DC, Muzik O, Behen M, Rothermel R, Janisse JJ, Lee J, Chugani HT: Developmental changes in brain serotonin synthesis capacity in autistic and nonautistic children. Ann Neurol 1999; 45:287-295.
44. Pierce K, Muller RA, Ambrose J, Allen G, Courchesne E: Face processing occurs outside the fusiform 'face area' in autism: Evidence from functional MRI. Brain 2001; 124:2059-2073.
45. 31P magnetic resonance spectroscopy studies. In: Bauman M, Kemper T, eds. The Neurobiology of Autism. Baltimore: Johns Hopkins University Press, 1994:86-101.
46. Rutter M: Infantile autism. In: Shaffer D, Ehrhardt AA, Greenhill LL, eds. The Clinical Guide to Child Psychiatry. New York: The Free Press, 1985:48-78.
47. Lord C, Rutter M, Le Couteur A: Autism Diagnostic Interview - Revised: A revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders. J Autism Dev Disord 1994; 24:659-685.
48. Rumsey JM, Rapoport JL, Sceery WR: Autistic children as adults: Psychiatric, social, and behavioral outcomes. J Am Acad Child Psychiatry 1985; 24:465-473.
49. Mundy P, Sigman M: The theoretical implications of joint-attention deficits in autism. Dev Psychopathol 1989; 1:173-183.
50. Kasari C, Sigman M, Mundy P, Yirmiya N: Affective sharing in the context of joint attention interactions of normal, autistic, and mentally retarded children. J Autism Dev Disord 1990; 20:87-94.
51. Asperger H: Die 'Autistischen Psychopathen' kindesalter. Arch Psychiatr Nervenkr 1944; 117:76-136.
52. Olsson B, Rett A: A review of the Rett syndrome with a theory of autism. Brain Dev 1990; 12:11-15.
53. Naidu S, Bibat G, Kratz L, Kelley RI, Pevsner J, Hoffman E, Cuffari C, Rohde C, Blue C, Johnson MV: Clinical variability in Rett's syndrome. J Child Neurol 2003; 18:662-668.
54. Kim SJ, Cook EH Jr: Novel de novo nonsense mutation of MECP2 in a patient with Rett Syndrome. Hum Mutat 2000; 15:382-383.
55. Volkmar F, Cohen D: Disintegrative disorder or 'late onset' autism. J Child Psychol Psychiat 1989; 30:717-724.
56. Corbett J, Harris R: Progressive disintegrative psychosis of childhood. J Child Psychol Psychiat 1977; 18:211-219.
57. Bartak L, Rutter M, Cox A: A comparative study of infantile autism and specific developmental receptive language disorder. I: The children. Br J Psychiatry 1975; 126:127-145.
58. Ornitz E, Ritvo E: The syndrome of autism: A critical review. Am J Psychiatry 1976; 133:609-621.
59. Lerman P, Lerman-Sagie T, Kivity S: Effect of early corticosteroid therapy for Landau-Kleffner syndrome. Dev Med Child Neurol 1991; 33:257-260.
60. Kolvin I, Fundudis T: Elective mute children: Psychological development and background factors. J Child Psychol Psychiat 1981; 22:219-232.
61. Hoffman-Plotkin D, Twentyman C: A multimodal assessment of behavioral and cognitive deficits in abused and neglected preschoolers. Child Dev 1984; 55:794-802.
62. Rutter M, Andersen-Wood L, Beckett C, Bredenkamp D, Castle J, Groothues C, Keaveney L, Lord C, O'Connor TG: Quasi-autistic patterns following severe early global privation. English and Romanian Adoptees (ERA) Study Team. J Child Psychol Psychiatry 1999; 40:537-549.
63. Lord C, Risi S, Lambrecht L, Cook EH Jr, Leventhal BL, DiLavore, Pickles A, Rutter M: The Autism Diagnostic Observation Schedule-Generic: A standard measure of social and communication deficits associated with the spectrum of autism. J Autism Dev Disor 2000; 30:205-223.
64. Schopler E, Reichler RJ, Renner BR: The Childhood Autism Rating Scale (CARS). Los Angeles, CA: Western Psychological Services, 1988.
65. Krug D, Arick J, Almond P: Behavior checklist for identifying severely handicapped individuals with high levels of autistic behavior. J Child Psychol Psychiat 1980; 21:221-229.
66. Aman M: Aberrant Behavior Checklist - Community Version. East Aurora, NY: Slosson Educational Publications, 1994.
67. de Bildt A, Kraijer D, Sytema S, Minderaa R: The psychometric properties of the Vineland Adaptive Behavior Scales in children and adolescents with mental retardation. J Autism Dev Disord 2005; 35(1):53-62.
68. Sparrow S, Balla D, Cicchetti D: Vineland Scales of Adaptive Behavior, Survey Form Manual. Circle Pines, MN: American Guidance Service, 1984.
69. Stutsman R: Merrill-Palmer Scale of Mental Tests. New York: Harcourt, Brace, and World, 1948.
70. Shah A, Holmes N: The use of the Leiter International Performance Scale with autistic children. J Autism Dev Disord 1985; 15:195-204.
71. Bayley N: Manual for the Bayley Scales of Infant Development. New York: Psychological Corporation, 1969.
72. Elliott C: Differential Abilities Scales. Pensacola, FL: Psychological Corporation, 1990.
73. Brown J: Adolescent development of children with infantile psychosis. Sem Psychiatry 1969; 1:79-89.
74. Kanner L, Rodriguez A, Ashenden B: How far can autistic children go in matters of social adaptation. J Aut Child Schizo 1972; 2:9-33.
75. Lotter V: Social adjustment and placement of autistic children in Middlesex: A follow-up study. J Aut Child Schizo 1974; 4:11-32.
76. Gillberg C: Autistic children growing up: Problems during puberty and adolescence. Dev Med Child Neurol 1984; 26:125-129.
77. Carr E: The motivation of self-injurious behavior: A review of some hypotheses. Psychological Bulletin 1977; 84:800-816.
78. Lord C: The development of peer relations in children with autism. In: Morrison F, Lord C, Keating D, eds. Applied Developmental Psychology. New York: Academic Press, 1984:165-229.
79. Campbell M, Schopler E, Cueva J, Hallin A: Treatment of autistic disorder. J Am Acad Child Adolesc Psychiatry 1996; 35:134-143.
80. Schopler E, Olley G: Comprehensive educational services for autistic children: The TEACCH model. In: Reynolds C, Gutkin T, eds. The Handbook of School Psychology. New York: John Wiley & Sons, 1982: 629-643.
81. Solnit A, Stark M: Mourning and the birth of a defective child. Psychoanalytic Study Child 1961; 16: 523-537.
82. Powers M: Children with Autism: A Parent's Guide. Bethesda, MD: Woodbine House, 1989.
83. Amenta C: Russell is Extra Special: A Book about Autism for Children. New York: Brunner/Mazel, 1992.
84. Siegel B, Silverstein S: What About Me? Growing Up with a Developmentally Disabled Sibling. New York: Plenum, 1994.
85. Cook E, Rowlett R, Jaselskis C, Leventhal B: Fluoxetine treatment of patients with autism and mental retardation. J Am Acad Child Adolesc Psychiatry 1992; 31:739-745.
86. Gordon C, State R, Nelson J, Hamburger S, Rapoport J: A double-blind comparison of clomipramine, desipramine, and placebo in the treatment of autistic disorder. Arch Gen Psychiatry 1993; 50:441-447.
87. McDougle C, Naylor S, Cohen D, Volkmar F, Heninger G, Price L: A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder. Arch Gen Psychiatry 1996; 53:1001-1008.
88. Posey DJ, Litwiller M, Koburn A, McDougle CJ: Paroxetine in autism. J Am Acad Child Adolesc Psychiatry 1999; 38:111-112.
89. Namerow LB, Thomas P, Bostic JQ, Prince J, Monuteaux MC: Use of citalopram in pervasive developmental disorders. J Dev Behav Pediatr 2003; 24:104-108.
90. Ghaziuddin M, Tsai L, Ghaziuddin N: Fluoxetine in autism with depression. J Am Acad Child Adolesc Psychiatry 1991; 30:508-509.
91. Owley T: The Pharmacological Treatment of Autistic Spectrum Disorders. CNS Spectrums 2002; 7:663-669
92. Quintana H, Birmaher B, Stedge D, Lennon S, Freed J, Bridge J, Greenhill L: Use of methylphenidate in the treatment of children with autistic disorder. J Autism Dev Disord 1995; 25:283-294.
93. Handen BL, Johnson CR, Lubetsky M: Efficacy of methylphenidate among children with autism and symptoms of attention-deficit hyperactivity disorder. J Autism Dev Disord 2000; 30:245-255.
94. Owley T, Walton L, Salt J, Guter S, Winnega M, Leventhal BL, Cook EH Jr: An open label trial of escitalopram in autistic spectrum disorders. J Am Acad Child Adolesc Psychiatry 2005; 44(4):343-348.
95. Fankhauser MP, Karumanchi VC, German ML, Yates A, Karumanchi SD: A double-blind, placebo-controlled study of the efficacy of transdermal clonidine in autism. J Clin Psychiatry 1992; 53:77-82.
96. Jaselskis CA, Cook EH, Fletcher KE, Leventhal BL: Clonidine treatment of hyperactive and impulsive children with autistic disorder. J Clin Psychopharm 1992; 12:322-327.
97. Williams DT, Mehl R, Yudofsky S, Adams D, Roseman B: The effect of propranolol on uncontrolled rage outbursts in children and adolescents with organic brain dysfunction. J Am Acad Child Psychiatry 1982 21(2): 129-135.
98. Ratey JJ, Mikkelsen E, Sorgi, P, Zuckerman HS, Polakoff S, Bemporad J, Bick P, Kadish W: Autism: The treatment of aggressive behaviors. J Clin Psychopharmacol 1987; 7(1):35-41.
99. Anderson LT, Campbell M, Adams P, Small AM, Perry R, Shell J: The effects of haloperidol on discrimination learning and behavioral symptoms in autistic children. J Aut Develop Disord 1989; 9:227-239.
100. Anderson LT, Campbell M, Grega DM, Perry R, Small AM, Green WH: Haloperidol in the treatment of infantile autism: Effects on learning and behavioral symptoms. Am J Psychiatry 1984; 141:1195-1202.
101. Campbell M, Anderson LT, Meier M, Cohen IL, Small AM, Samit C, Sachar EJ: A comparison of haloperidol and behavior therapy and their interaction in autistic children. J Am Acad Child Psychiatry 1976; 17:640-655.
102. Cohen IL, Campbell M, Posner D, Small AM, Triebel D, Anderson LT: Behavioral effects of haloperidol in young autistic children. An objective analysis using a within subject reversal design. J Am Acad Child Psychiatry 1980; 19:665-677.
103. Ernst M, Magee HJ, Gonzalez NM, Locascio JJ, Rosenberg CR, Campbell M: Pimozide in autistic children. Psychopharmacol Bull 1992; 28:187-191.
104. Fish B, Shapiro T, Campbell M: Long-term prognosis and the response of schizophrenic children to drug therapy: A controlled study of trifluoperazine. Am J Psychiatry 1966; 123:32-39.
105. Naruse H, Nagahata M, Nakane Y, Shirahashi K, Takesada M, Yamazaki K: A multi-center double-blind trial of pimozide (Orap), haloperidol and placebo in children with behavioral disorders, using crossover design. Acta Paedopsychiat 1982; 48:173-184.
106. Perry R, Campbell M, Adams P, Lynch N, Spencer EK, Curren EL, Overall JE: Long-term efficacy of haloperidol in autistic children: Continuous versus discontinuous drug administration. J Am Acad Child Adolesc Psychiatry 1989; 28(1):87-92.
107. Campbell M, Adams P, Perry R, Spencer EK, Overall JE: Tardive and withdrawal dyskinesia in autistic children: A prospective study. Psychopharm Bull 1988; 24:251-255
108. Campbell M, Armenteros JL, Malone RP, Adams PB, Eisenberg ZW, Overall JE: Neuroleptic-related dyskinesias in autistic children: A prospective, longitudinal study. J Am Acad Child Adolesc Psychiatry 1997;36(6): 835-843.
109. O'Brien J, Barber R: Marked improvement in tardive dyskinesia following treatment with olanzapine in an elderly subject. Br J Psychiatry 1998; 172:186.
110. Malone RP, Cater J, Sheikh RM, Choudhury MS, Delaney MA: Olanzapine versus haloperidol in children with autistic disorder: An open pilot study. J Am Acad Child Adolesc Psychiatry 2001; 40:887-894.
111. Masi G, Cosenza A, Mucci M, Brovedani P: Open trial of risperidone in 24 young children with pervasive developmental disorders. J Am Acad Child Adolesc Psychiatry 2001; 40:1206-1214.
112. McDougle CJ, Holmes JP, Bronson MR, Anderson GM, Volkmar FR, Price LH, Cohen DJ: Risperidone treatment of children and adolescents with pervasive developmental disorders: A prospective open-label study. J Am Acad Child Adolesc Psychiatry 1997; 36:685-693.
113. Potenza MN, Holmes JP, Kanes SJ, McDougle CJ: Olanzapine treatment of children, adolescents, and adults with pervasive developmental disorders: An open-label pilot study. J Clin Psychopharmacol 1999; 19:37-44.
114. Nicolson R, Awad G, Sloman L: An open trial of risperidone in young autistic children. J Am Acad Child Adolesc Psychiatry 1998; 37(4):372-376.
115. McDougle CJ, Holmes JP, Carlson DC, Pelton GH, Cohen DJ, Price LH: A double-blind, placebocontrolled study of risperidone in adults with autistic disorder and other pervasive developmental disorders. Arch Gen Psychiatry 1998; 55:633-641.
116. McCracken JT, McGough J, Shah B, Cronin P, Hong D, Aman MG, Arnold LE, Lindsay R, Nash P, Hollway J, McDougle CJ, Posey D, Swiezy N, Kohn A, Scahill L, Martin A, Koenig K, Volkmar F, Carroll D, Lancor A, Tierney E, Ghuman J, Gonzalez NM, Grados M, Vitiello B, Ritz L, Davies M, Robinson J, McMahon D: Risperidone in children with autism and serious behavioral problems. N Engl J Med 2002; 347:314-321.
117. Masi G, Cosenza A, Mucci M, Brovedani P: A 3-year naturalistic study of 53 preschool children with pervasive developmental disorders treated with risperidone. J Clin Psychiatry 2003; 64(9):1039-1047.
118. Gagliano A, Germano E, Pustorino G, Impallomeni C, D'Arrigo C, Calamoneri F, Spina E: Risperidone treatment of children with autistic disorder: Effectiveness, tolerability, and pharmacokinetic implications. J Child Adolesc Psychopharmacol 2004; 14(1):39-47.
119. Kemner C, Willemsen-Swinkels SH, de Jonge M, Tuynman-Qua H, van Engeland H: Open-label study olanzapine in children with pervasive developmental disorder. J Clin Psychopharmacol 2002; 22: 455-460.
120. Cohen SA, Fitzgerald BJ, Khan SR, Khan A: The effect of a switch to ziprasidone in an adult population with autistic disorder: Chart review of naturalistic, openlabel treatment. J Clin Psychiatry 2004; 65:110-113.
121. Hollander E, Dolgoff-Kaspar R, Cartwright C, Rawitt R, Novotny S: An open trial of divalproex sodium in autism spectrum disorders. J Clin Psychiatry 2001; 62:530-534.
122. Brent DA, Crumrine PK, Varma RR, Allan M, Allman C: Phenobarbital treatment and major depressive disorder in children with epilepsy. Pediatrics 1987; 80:909-917.
123. Vining EPG, Mellits D, Dorsen MM, Cataldo MF, Quaskey SA, Spielberg SP, Freeman JM: Psychologic and behavioral effects of antiepileptic drugs in children: A double-blind comparison between phenobarbital and valproic acid. Pediatrics 1987; 80:165-174.
124. Plioplys AV: Autism: electroencephalogram abnormalities and clinical improvement with valproic acid. Arch Pediatrics Adolesc Med 1994; 24(1):23-37.
125. Campbell M, Anderson L, Small A, Adams P, Gonzalez N, Ernst M: Naltrexone in autistic children: Behavioral symptoms and attentional learning. J Am Acad Child Adolesc Psychiatry 1993; 32:1283-1291.
126. Willemsen-Swinkels SHN, Buitelaar JK, Weijnen FG, Van Engeland H: Placebo-controlled acute dosage naltrexone study in young autistic children. Psychiatry Res 1995; 58:203-215.
127. Feldman HM, Kolmen BK, Gonzaga AM: Naltrexone and communication skills in young children with autism. J Am Acad Child Adolesc Psychiatry 1999; 38(5):587-593.
128. Herman BH, Hammock MK, Egan J, Arthur-Smith A, Chatoor I, Werner A: Peptides in self-injurious behavior: Dissociation from autonomic nervous system functioning. Dev Pharmacol Therapeut 1989; 12:81-89.
129. Willemsen-Swinkels SH, Buitelaar JK, van Berckelaer-Onnes IA, van Engeland H: Brief report: Six months continuation treatment in naltrexone-responsive children with autism: An open-label case-control design. J Autism Dev Disord 1999; 29:167-169.
130. Willemsen-Swinkels SHN, Buitelaar JK, Van Engeland H: The effects of chronic naltrexone treatment in young autistic children: A double-blind placebocontrolled crossover study. Biol Psychiatry 1996; 39: 1023-1031.
131. Percy AK, Glaze DG, Schultz RJ, Zoghbi HY, Williamson D, Frost J Jr., Jankovic JJ, del Junco D, Skender M, Waring S, et al.: Rett syndrome: Controlled study of an oral opiate antagonist, naltrexone. Ann Neurol 1994; 35:464-470.
132. Campbell M, Fish B, Korein J, Shapiro T, Collins P, Koh C: Lithium and chlorpromazine: A controlled crossover study of hyperactive severely disturbed young children. J Autism Child Schizophr 1972; 2:234-263.
133. Buitelaar JK, van der Gaag RJ, van der Hoeven J: Buspirone in the management of anxiety and irritability in children with pervasive developmental disorders: Results of an open label study. J Clin Psychiatry 1998; 56:56-59.
134. Carlsson ML: Hypothesis: is infantile autism a hypoglutamatergic disorder? Relevance of glutamate - serotonin interactions for pharmacotherapy. J Neural Transm 1998; 105:525-35.
135. King B, Wright D, Handen B, Sikich L, Zimmerman A, McMahon W, Cantwell E, et al.: A double-blind, placebo-controlled study of amantidine hydrochloride in the treatment of children with autistic disorder. J Am Acad Child Adolesc Psychiatry 2001; 40:658-665.
136. Martineau J, Barthelemy C, Cheliakine C, Lelord G: Brief report: An open middle-term study of combined vitamin B6-magnesium in a subgroup of autistic children selected on their sensitivity to this treatment. J Autism Dev Disord 1988; 18(3):435-447.
137. Kleijnen J, Knipschild P: Niacin and vitamin B6 in mental functioning: A review of controlled trials in humans. Biol Psychiatry 1991; 29:931-941.
138. Pfeiffer SI, Norton J, Nelson L, Shott S: Efficacy of vitamin B6 and magnesium in the treatment of autism: A methodology review and summary of outcomes. J Autism Dev Disord 1995; 25:481-493.
139. Geller E, Ritvo ER, Freeman BJ, Yuwiler A: Preliminary observations on the effect of fenfluramine on blood serotonin and symptoms in three autistic boys. N Engl J Med 1982; 307(3):165-169.
140. Aman MG, Kern RA: Review of fenfluramine in the treatment of the developmental disabilities. J Am Acad Child and Adolesc Psychiatry 1989; 28: 549-565.
141. Leventhal B, Cook E, Morford M, Ravitz A, Heller W, Freedman D: Fenfluramine: Clinical and neurochemical effects in children with autism. J Neuropsychiatry Clin Neurosci 1993; 5:307-315.
142. Aman MG, Kern RA, Arnold LE, McGhee DE: Fenfluramine and mental retardation. J Am Acad Child Adolesc Psychiatry 1991; 30:507-508.
143. Schuster CR, Lewis M, Seiden LS: Fenfluramine: Neurotoxicity. Psychopharm Bull 1986; 22:148-151.
144. Horvath K, Stefanatos G, Sokolski KN, Wachtel R, Nabors L, Tildon JT: Improved social and language skills after secretin administration in patients with autistic spectrum disorders. J Assoc Acad Minor Phys 1998; 9:9-15.
145. Chez MG, Buchanan CP, Bagan BT, Hammer MS, McCarthy KS, Ovrutskaya I, Nowinski CV, et al.: Secretin and autism: A two-part clinical investigation. J Autism Dev Disord 2000; 30:87-94.
146. Coniglio SJ, Lewis JD, Lang C, Burns TG, Subhani-Siddique R, Weintraub A, Schub H, et al.: A randomized, double-blind, placebo-controlled trial of single-dose intravenous secretin as treatment for children with autism. J Pediatr 2001; 138:649-655.
147. Dunn-Geier J, Ho HH, Auersperg E, Doyle D, Eaves L, Matsuba C, Orrbine E, et al.: Effect of secretin on children with autism: A randomized controlled trial. Dev Med Child Neurol 2000; 42:796-802.
148. Levy SE, Souders MC, Wray J, Jawad AF, Gallagher PR, Coplan J, Belchic JK, Gerdes M, Mitchell R, Mulberg AE: Children with autistic spectrum disorders. I: Comparison of placebo and single dose of human synthetic secretin. Arch Dis Child 2003; 88(8):731-736.
149. Molloy CA, Manning-Courtney P, Swayne S, Bean J, Brown JM, Murray DS, Kinsman AM, Brasington M, Ulrich CD 2nd: Lack of benefit of intravenous synthetic human secretin in the treatment of autism. J Autism Dev Disord 2002; 32(6):545-551.
150. Owley T, McMahon W, Cook EH, Laulhere TM, South M, Mays LZ, Shernoff ES, et al.: Multi-site, doubleblind, placebo-controlled trial of porcine secretin in autism. J Am Acad Child Adolesc Psychiatry 2001; 40:1293-1299.
151. Roberts W, Weaver L, Brian J, Bryson S, Emelianova S, Griffiths AM, MacKinnon B, et al.: Repeated doses of porcine secretin in the treatment of autism: A randomized, placebo-controlled trial. Pediatrics 2001; 107:E71.
152. Sandler AD, Sutton KA, DeWeese J, Girardi MA, Sheppard V, Bodfish JW: Lack of benefit of a single dose of synthetic human secretin in the treatment of autism and pervasive developmental disorder. N Engl J Med 1999; 341:1801-1806.
153. Unis AS, Munson JA, Rogers SJ, Goldson E, Osterling J, Gabriels R, Abbott RD, Dawson G: A randomized, double-blind, placebo-controlled trial of porcine versus synthetic secretin for reducing symptoms of autism. J Am Acad Child Adolesc Psychiatry 2002; 41(11): 1315-1321.